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A 96-condition initial screen for protein crystallization, called MORPHEUS, has
been developed at the MRC Laboratory of Molecular Biology, Cambridge,
England (MRC-LMB). The concept integrates several innovative approaches,
such as chemically compatible mixesof potential ligands, new buffer systems and
precipitant mixes that also act as cryoprotectants. Instead of gathering a set of
crystallization conditions that have already been successful, a selection of
molecules frequently observed in the Protein Data Bank (PDB) to co-crystallize
with proteins has been made. These have been put together in mixes of similar
chemical behaviour and structure, and combined with buffers and precipitant
mixes that were also derived from PDB searches, to build the screen de novo.
Observations made at the MRC-LMB and many practical aspects were also
taken into account when formulating the screen. The resulting screen is easy to
use, comprehensive yet small, and has already yielded a list of crystallization hits
using both known and novel samples. As an indicator of success, the screen has
now become one of the standard screens used routinely at the MRC-LMB when
searching initial crystallization conditions for biological macromolecules.
1. Introduction
Structure determination of biological macromolecules has
been tremendously successful over recent years. The Protein
Data Bank (PDB, http://www.pdb.org; Berman et al., 2000)
now holds nearly 60 000 coordinate sets. Approximately 80%
of those have been determined by X-ray crystallography, and
the method, since its ﬁrst application to biological macro-
molecules more than 50 years ago (Kendrew et al., 1958;
Perutz et al., 1960), has continued to improve. Recently, the
atomic structure of the complete 70S ribosome was deter-
mined using X-ray crystallography (Selmer et al., 2006). Given
the obvious successes, one might be forgiven for assuming that
the basis of the method, the crystallization of a protein, DNA
or RNA and their complexes, must be an easy process. In fact,
crystallization is now rate limiting and a typical project trying
to elucidate the structure of a biological macromolecule of
interest will spend most time trying to obtain a sample of
biological interest that can be crystallized (Chayen & Sari-
dakis, 2008). The underlying problem is that at the time of the
crystallization experiment the structure of the molecule is not
known and hence a rational approach cannot be taken.
To circumvent this problem, crystallization screens are
utilized which try to sample the vast number of possible
variables in a manageable and efﬁcient way, either system-
atically or randomly (McPherson, 2004). Development of an
effective search strategy depends on determining how para-
meter variations inﬂuence crystal formation and crystal
quality (Kingston et al., 1994). The protein itself can be
considered as the main variable (Dale et al., 2003). However,
the correct composition of the initial crystallization screen is
necessary, although by no means sufﬁcient, for success.
Nowadays, vapour diffusion with 50–200 nl drops is the
most widespread crystallization technique and many different
commercial screening kits are available to initiate experiments
(Berry et al., 2006). Many screens are systematic variations of
the concentrations or chemical nature of the components and
others employ so-called sparse-matrix approaches that are
essentially collections of conditions (mixes of reagents used
for protein crystallization) that have been found to work
previously with other samples (Jancarik & Kim, 1991).
The increasing number of structures deposited in the PDB
has motivated some statistical analyses of the crystallization
conditions employed (Hennessy et al., 2000; Kantardjieff &
Rupp, 2004), together with attempts to rationalize protein
crystallization screens (Zhu et al., 2006; Newstead et al., 2008).
Rationalization has led to screens with a minimal number of
conditions in sparse matrices and footprint screens (Brzo-
zowski & Walton, 2001; Radaev & Sun, 2002; Tran et al., 2004;
Newman et al., 2005). This is logical if overall efﬁciency is the
main goal, such as in structural genomics.
At the MRC Laboratory of Molecular Biology (Cambridge,
England), protein samples, DNA–protein complexes and
RNA-containing complexes are regularly screened using
standard procedures with more than 40 commercial initial
screen kits (Stock et al., 2005) and over 1500 conditions,
assembled into pre-ﬁlled MRC 96-well crystallization plates.
This large number is still not large enough because many
samples fail to crystallize or give only a very few hits. Amongst
others, this could be due to two main reasons. Firstly, the vast
number of possible conditions is under-sampled (which issurely true). Secondly, crystallization can be critically depen-
dent on the component(s) in the screen (St John et al., 2008)
that make proteins behave differently (more stable or rigid,
for example). The latter reason is the rationale behind clas-
sical additive screening (Cudney et al., 1994) and a recent
development called Silverbullets (McPherson & Cudney,
2006).
Both assumptions were a driving force behind my attempts
to formulate the new screen MORPHEUS that could enhance
the chances of crystallization. The most important feature of
MORPHEUS is the inclusion of mixes containing potential
ligands and additives that can promote crystallization through
speciﬁc interactions. This strategy includes the risk that one
component of a mix might have a deleterious effect on crystal
growth (or complex association) and thereby mask the posi-
tive contribution of another (Larson et al., 2007). By selecting
components that have been seen to be ordered in crystal
structures in the PDB, the chances of incorporating molecules
playing a positive role should increase.
An extensive search of the PDB was performed and small
molecules and ions that bind to biological macromolecules
were selected. The molecules are stable, commercially avail-
able, have a molecular weight below 250 Da and are easy to
handle. Components found abundantly in the PDB are
potentially good crystallization agents for two reasons. Firstly,
they can be stabilizers. For example, some sugars are well
known for their thermodynamic stabilization of macro-
molecules (Arakawa & Timasheff, 1982). Stabilization can
also mean ‘rigidifying’ the protein or the crystal lattice and
thus improving diffraction quality. Secondly, ligands can create
crystallization variants by changing possible interactions on
the molecular surface, hence increasing the chances of
obtaining different crystals. From this perspective, small
counter-anions like nitrate, phosphate and sulfate, with a
multitude of possible binding modes via different spatial
arrangements of O atoms, are ideal components. For the same
reason, small organic salts with carboxylic acid groups can
facilitate crystal growth (McPherson, 2001). Additional agents
found frequently in the PDB include halides that promote
different crystal forms (Lim et al., 1998) and can help with
crystallographic phase determination (Dauter et al., 2000). It
has been shown that polyethylene glycols (PEGs) tend to form
linear binding patterns in clefts on protein surfaces (Hasek,
2006). Therefore, a selection of six PEGs completes the
formulation of MORPHEUS.
MORPHEUS provides 96 original conditions made from
innovative mixes of potential ligands that have been found
with high frequency in the PDB. Will MORPHEUS, like the
Greek god of dreams, take different forms, especially those in
the shape of crystals? Here, ideas about the formulations and
the results from crystallization experiments using test proteins
and novel samples are described, proving the high usability
and efﬁciency of MORPHEUS.
2. Materials and methods
The complete formulation of MORPHEUS is shown in
Table 1. Fig. 1 is a schematic representation of the screen
layout.
2.1. Selection of PDB-derived ligands
The set of 47 PDB-derived ligands is listed in Table 2.
Initially, structures with ligand(s) were tabulated (July, 2008).
Data were then ﬁltered with a molecular weight cut-off of
250 Da. The resulting list was ﬁltered again to keep only
ligands seen with at least ﬁve unrelated protein structures.
Not included in MORPHEUS because of chemical incom-
patibility are all phenols, heavy atoms and detergents. Many
divalent cations and some carboxylic acids were discarded in
later tests because of problems with stability and false posi-
tives. Also, there is a limit to the number of ligands (i.e.
additives) that can be integrated into 96 conditions. Concen-
trations must be high because low afﬁnities should be
considered (Sauter et al., 1999).
2.2. Additive mixes
Thirty-eight of the selected PDB-derived ligands have been
grouped into families depending on their chemical nature to
form eight additive mixes. For example, one of the additive
mixes is composed of n-ethylene glycols (n = 2–5). By
grouping the additives based on chemical nature, the possi-
bility of cross-reaction is avoided and stock solutions are
stable. When additives were salts with an acid or base form,
the salts were selected so that the ﬁnal pH of the mix was as
neutral as possible. A compound-to-protein ratio of 10:1 is
commonly adopted for co-crystallization with small molecule
ligands (Danley, 2006) and hence the ﬁnal concentration of
each additive in MORPHEUS is 0.02 M minimum, repre-
senting ten times the concentration of a 10 kDa protein at
20 mg ml
 1. The recipes for preparing the eight MORPHEUS
additive mixes can be found in Table 3.
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Figure 1
MORPHEUS schematic screen layout.research papers
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Table 1
Formulation of MORPHEUS.
PEG MME is polyethylene glycol monomethyl ether. MPD is (RS)-2-methyl-2,4-pentanediol. NPS is a mix containing sodium nitrate, disodium hydrogen
phosphate and ammonium sulfate.
Well Mix of precipitants Mix of additives Buffer system
A1 10% w/v PEG 20 000, 20% v/v PEG MME 550 0.03 M of each divalent cation 0.1 M MES/imidazole pH 6.5
A2 10% w/v PEG 8000, 20% v/v ethylene glycol 0.03 M of each divalent cation 0.1 M MES/imidazole pH 6.5
A3 10% w/v PEG 4000, 20% v/v glycerol 0.03 M of each divalent cation 0.1 M MES/imidazole pH 6.5
A4 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD 0.03 M of each divalent cation 0.1 M MES/imidazole pH 6.5
A5 10% w/v PEG 20 000, 20% v/v PEG MME 550 0.03 M of each divalent cation 0.1 M MOPS/HEPES-Na pH 7.5
A6 10% w/v PEG 8000, 20% v/v ethylene glycol 0.03 M of each divalent cation 0.1 M MOPS/HEPES-Na pH 7.5
A7 10% w/v PEG 4000, 20% v/v glycerol 0.03 M of each divalent cation 0.1 M MOPS/HEPES-Na pH 7.5
A8 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD 0.03 M of each divalent cation 0.1 M MOPS/HEPES-Na pH 7.5
A9 10% w/v PEG 20 000, 20% v/v PEG MME 550 0.03 M of each divalent cation 0.1 M bicine/Trizma base pH 8.5
A10 10% w/v PEG 8000, 20% v/v ethylene glycol 0.03 M of each divalent cation 0.1 M bicine/Trizma base pH 8.5
A11 10% w/v PEG 4000, 20% v/v glycerol 0.03 M of each divalent cation 0.1 M bicine/Trizma base pH 8.5
A12 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD 0.03 M of each divalent cation 0.1 M bicine/Trizma base pH 8.5
B1 10% w/v PEG 20 000, 20% v/v PEG MME 550 0.03 M of each halide 0.1 M MES/imidazole pH 6.5
B2 10% w/v PEG 8000, 20% v/v ethylene glycol 0.03 M of each halide 0.1 M MES/imidazole pH 6.5
B3 10% w/v PEG 4000, 20% v/v glycerol 0.03 M of each halide 0.1 M MES/imidazole pH 6.5
B4 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD 0.03 M of each halide 0.1 M MES/imidazole pH 6.5
B5 10% w/v PEG 20 000, 20% v/v PEG MME 550 0.03 M of each halide 0.1 M MOPS/HEPES-Na pH 7.5
B6 10% w/v PEG 8000, 20% v/v ethylene glycol 0.03 M of each halide 0.1 M MOPS/HEPES-Na pH 7.5
B7 10% w/v PEG 4000, 20% v/v glycerol 0.03 M of each halide 0.1 M MOPS/HEPES-Na pH 7.5
B8 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD 0.03 M of each halide 0.1 M MOPS/HEPES-Na pH 7.5
B9 10% w/v PEG 20 000, 20% v/v PEG MME 550 0.03 M of each halide 0.1 M bicine/Trizma base pH 8.5
B10 10% w/v PEG 8000, 20% v/v ethylene glycol 0.03 M of each halide 0.1 M bicine/Trizma base pH 8.5
B11 10% w/v PEG 4000, 20% v/v glycerol 0.03 M of each halide 0.1 M bicine/Trizma base pH 8.5
B12 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD 0.03 M of each halide 0.1 M bicine/Trizma base pH 8.5
C1 10% w/v PEG 20 000, 20% v/v PEG MME 550 0.03 M of each NPS 0.1 M MES/imidazole pH 6.5
C2 10% w/v PEG 8000, 20% v/v ethylene glycol 0.03 M of each NPS 0.1 M MES/imidazole pH 6.5
C3 10% w/v PEG 4000, 20% v/v glycerol 0.03 M of each NPS 0.1 M MES/imidazole pH 6.5
C4 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD 0.03 M of each NPS 0.1 M MES/imidazole pH 6.5
C5 10% w/v PEG 20 000, 20% v/v PEG MME 550 0.03 M of each NPS 0.1 M MOPS/HEPES-Na pH 7.5
C6 10% w/v PEG 8000, 20% v/v ethylene glycol 0.03 M of each NPS 0.1 M MOPS/HEPES-Na pH 7.5
C7 10% w/v PEG 4000, 20% v/v glycerol 0.03 M of each NPS 0.1 M MOPS/HEPES-Na pH 7.5
C8 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD 0.03 M of each NPS 0.1 M MOPS/HEPES-Na pH 7.5
C9 10% w/v PEG 20 000, 20% v/v PEG MME 550 0.03 M of each NPS 0.1 M bicine/Trizma base pH 8.5
C10 10% w/v PEG 8000, 20% v/v ethylene glycol 0.03 M of each NPS 0.1 M bicine/Trizma base pH 8.5
C11 10% w/v PEG 4000, 20% v/v glycerol 0.03 M of each NPS 0.1 M bicine/Trizma base pH 8.5
C12 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD 0.03 M of each NPS 0.1 M bicine/Trizma base pH 8.5
D1 10% w/v PEG 20 000, 20% v/v PEG MME 550 0.02 M of each alcohol 0.1 M MES/imidazole pH 6.5
D2 10% w/v PEG 8000, 20% v/v ethylene glycol 0.02 M of each alcohol 0.1 M MES/imidazole pH 6.5
D3 10% w/v PEG 4000, 20% v/v glycerol 0.02 M of each alcohol 0.1 M MES/imidazole pH 6.5
D4 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD 0.02 M of each alcohol 0.1 M MES/imidazole pH 6.5
D5 10% w/v PEG 20 000, 20% v/v PEG MME 550 0.02 M of each alcohol 0.1 M MOPS/HEPES-Na pH 7.5
D6 10% w/v PEG 8000, 20% v/v ethylene glycol 0.02 M of each alcohol 0.1 M MOPS/HEPES-Na pH 7.5
D7 10% w/v PEG 4000, 20% v/v glycerol 0.02 M of each alcohol 0.1 M MOPS/HEPES-Na pH 7.5
D8 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD 0.02 M of each alcohol 0.1 M MOPS/HEPES-Na pH 7.5
D9 10% w/v PEG 20 000, 20% v/v PEG MME 550 0.02 M of each alcohol 0.1 M bicine/Trizma base pH 8.5
D10 10% w/v PEG 8000, 20% v/v ethylene glycol 0.02 M of each alcohol 0.1 M bicine/Trizma base pH 8.5
D11 10% w/v PEG 4000, 20% v/v glycerol 0.02 M of each alcohol 0.1 M bicine/Trizma base pH 8.5
D12 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD 0.02 M of each alcohol 0.1 M bicine/Trizma base pH 8.5
E1 10% w/v PEG 20 000, 20% v/v PEG MME 550 0.03 M of each ethylene glycol 0.1 M MES/imidazole pH 6.5
E2 10% w/v PEG 8000, 20% v/v ethylene glycol 0.03 M of each ethylene glycol 0.1 M MES/imidazole pH 6.5
E3 10% w/v PEG 4000, 20% v/v glycerol 0.03 M of each ethylene glycol 0.1 M MES/imidazole pH 6.5
E4 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD 0.03 M of each ethylene glycol 0.1 M MES/imidazole pH 6.5
E5 10% w/v PEG 20 000, 20% v/v PEG MME 550 0.03 M of each ethylene glycol 0.1 M MOPS/HEPES-Na pH 7.5
E6 10% w/v PEG 8000, 20% v/v ethylene glycol 0.03 M of each ethylene glycol 0.1 M MOPS/HEPES-Na pH 7.5
E7 10% w/v PEG 4000, 20% v/v glycerol 0.03 M of each ethylene glycol 0.1 M MOPS/HEPES-Na pH 7.5
E8 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD 0.03 M of each ethylene glycol 0.1 M MOPS/HEPES-Na pH 7.5
E9 10% w/v PEG 20 000, 20% v/v PEG MME 550 0.03 M of each ethylene glycol 0.1 M bicine/Trizma base pH 8.5
E10 10% w/v PEG 8000, 20% v/v ethylene glycol 0.03 M of each ethylene glycol 0.1 M bicine/Trizma base pH 8.5
E11 10% w/v PEG 4000, 20% v/v glycerol 0.03 M of each ethylene glycol 0.1 M bicine/Trizma base pH 8.5
E12 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD 0.03 M of each ethylene glycol 0.1 M bicine/Trizma base pH 8.5
F1 10% w/v PEG 20 000, 20% v/v PEG MME 550 0.02 M of each monosaccharide 0.1 M MES/imidazole pH 6.5
F2 10% w/v PEG 8000, 20% v/v ethylene glycol 0.02 M of each monosaccharide 0.1 M MES/imidazole pH 6.5
F3 10% w/v PEG 4000, 20% v/v glycerol 0.02 M of each monosaccharide 0.1 M MES/imidazole pH 6.5
F4 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD 0.02 M of each monosaccharide 0.1 M MES/imidazole pH 6.5
F5 10% w/v PEG 20 000, 20% v/v PEG MME 550 0.02 M of each monosaccharide 0.1 M MOPS/HEPES-Na pH 7.5
F6 10% w/v PEG 8000, 20% v/v ethylene glycol 0.02 M of each monosaccharide 0.1 M MOPS/HEPES-Na pH 7.5
F7 10% w/v PEG 4000, 20% v/v glycerol 0.02 M of each monosaccharide 0.1 M MOPS/HEPES-Na pH 7.5
F8 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD 0.02 M of each monosaccharide 0.1 M MOPS/HEPES-Na pH 7.52.3. Precipitant mixes
Precipitants can be mixed to have a synergistic effect
(Majeed et al., 2003) and/or to provide cryoprotection
(Mitchell & Garman, 1994; McFerrin & Snell, 2002). To take
advantage of these ﬁndings, four precipitant mixes were
integrated in the formulation of MORPHEUS. Three of the
mixes have been observed to be more successful in the crys-
tallization of MRC-LMB samples than expected from their
under-sampling in our initial screens, as described previously.
A fourth mix was designed from scratch with components not
found in the other three mixes. Principally, the precipitant
mixes have been chosen so that the ﬁnal conditions produce
vitriﬁed ice when frozen. It should be noted, however, that the
optimal concentration of cryoprotectant is sample dependent
and may need optimization later (Chinte et al., 2005). Recipes
for preparing the four MORPHEUS stock solutions with
precipitants can be found in Table 4. The table includes the
frequency of similar mixes in our MRC-LMB standard initial
screens.
2.4. Buffer systems
Six of the selected PDB-derived ligands described before
have been used to build three buffer systems within a
physiological pH range, namely 6.5, 7.5 and 8.5. The common
advantage of buffer systems is that no titration with concen-
trated acid or base is required (Newman, 2004). Each
MORPHEUS buffer system includes an acid and base pair of
buffers with similar pKa values. This way, the systems combine
the characteristics of two different Good buffers for biological
research (Good et al., 1966).
Recipes for preparing 50 ml of the three MORPHEUS
buffer systems can be found in Table 5. Non-titrated stock
solutions of the individual buffers (at a concentration of 1 M)
were mixed at different ratios for optimization purposes.
The chemicals used for making the buffer systems were
MES [2-(N-morpholino)ethanesulfonic acid; Sigma, M8250,
pH 2.7], imidazole (1,3-diazacyclopenta-2,4-diene; BDH,
286874D, pH 9.9), MOPS [3-(N-morpholino)propanesulfonic
acid; BDH, 4438321, pH 2.9], HEPES-Na [sodium 4-(2-
hydroxyethyl)piperazine-1-ethanesulfonate; Melford, B2001,
pH 10.4], bicine [N,N-bis(2-hydroxyethyl)glycine; Fluka,
14871, pH 4.9] and Trizma base [proprietary Tris, 2-amino-2-
(hydroxymethyl)-1,3-propanediol; Sigma, T1503, pH 10.6].
The pH was measured at 294 K with an InLab 490 solid-state
probe (Mettler–Toledo) to avoid inaccuracies with Tris-
containing buffers.
2.5. Stability tests
The stability of the conditions during their development was
assessed by checking the turbidity and pH after one week at
293 K, one week at 277 K and another week at 293 K.
2.6. Proteins
For details of the proteins used, please refer to Table 6.
2.7. Crystallization trials
MRC crystallization plates (Swissci) containing
MORPHEUS (85 ml in the main wells) were prepared on a
Mosquito (TTP labtech) or ScreenMaker (Innovadyne)
nanolitre liquid handler. Our standard setup for initial screens
research papers
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Table 1 (continued)
Well Mix of precipitants Mix of additives Buffer system
F9 10% w/v PEG 20 000, 20% v/v PEG MME 550 0.02 M of each monosaccharide 0.1 M bicine/Trizma base pH 8.5
F10 10% w/v PEG 8000, 20% v/v ethylene glycol 0.02 M of each monosaccharide 0.1 M bicine/Trizma base pH 8.5
F11 10% w/v PEG 4000, 20% v/v glycerol 0.02 M of each monosaccharide 0.1 M bicine/Trizma base pH 8.5
F12 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD 0.02 M of each monosaccharide 0.1 M bicine/Trizma base pH 8.5
G1 10% w/v PEG 20 000, 20% v/v PEG MME 550 0.02 M of each carboxylic acid 0.1 M MES/imidazole pH 6.5
G2 10% w/v PEG 8000, 20% v/v ethylene glycol 0.02 M of each carboxylic acid 0.1 M MES/imidazole pH 6.5
G3 10% w/v PEG 4000, 20% v/v glycerol 0.02 M of each carboxylic acid 0.1 M MES/imidazole pH 6.5
G4 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD 0.02 M of each carboxylic acid 0.1 M MES/imidazole pH 6.5
G5 10% w/v PEG 20 000, 20% v/v PEG MME 550 0.02 M of each carboxylic acid 0.1 M MOPS/HEPES-Na pH 7.5
G6 10% w/v PEG 8000, 20% v/v ethylene glycol 0.02 M of each carboxylic acid 0.1 M MOPS/HEPES-Na pH 7.5
G7 10% w/v PEG 4000, 20% v/v glycerol 0.02 M of each carboxylic acid 0.1 M MOPS/HEPES-Na pH 7.5
G8 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD 0.02 M of each carboxylic acid 0.1 M MOPS/HEPES-Na pH 7.5
G9 10% w/v PEG 20 000, 20% v/v PEG MME 550 0.02 M of each carboxylic acid 0.1 M bicine/Trizma base pH 8.5
G10 10% w/v PEG 8000, 20% v/v ethylene glycol 0.02 M of each carboxylic acid 0.1 M bicine/Trizma base pH 8.5
G11 10% w/v PEG 4000, 20% v/v glycerol 0.02 M of each carboxylic acid 0.1 M bicine/Trizma base pH 8.5
G12 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD 0.02 M of each carboxylic acid 0.1 M bicine/Trizma base pH 8.5
H1 10% w/v PEG 20 000, 20% v/v PEG MME 550 0.02 M of each amino acid 0.1 M MES/imidazole pH 6.5
H2 10% w/v PEG 8000, 20% v/v ethylene glycol 0.02 M of each amino acid 0.1 M MES/imidazole pH 6.5
H3 10% w/v PEG 4000, 20% v/v glycerol 0.02 M of each amino acid 0.1 M MES/imidazole pH 6.5
H4 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD 0.02 M of each amino acid 0.1 M MES/imidazole pH 6.5
H5 10% w/v PEG 20 000, 20% v/v PEG MME 550 0.02 M of each amino acid 0.1 M MOPS/HEPES-Na pH 7.5
H6 10% w/v PEG 8000, 20% v/v ethylene glycol 0.02 M of each amino acid 0.1 M MOPS/HEPES-Na pH 7.5
H7 10% w/v PEG 4000, 20% v/v glycerol 0.02 M of each amino acid 0.1 M MOPS/HEPES-Na pH 7.5
H8 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD 0.02 M of each amino acid 0.1 M MOPS/HEPES-Na pH 7.5
H9 10% w/v PEG 20 000, 20% v/v PEG MME 550 0.02 M of each amino acid 0.1 M bicine/Trizma base pH 8.5
H10 10% w/v PEG 8000, 20% v/v ethylene glycol 0.02 M of each amino acid 0.1 M bicine/Trizma base pH 8.5
H11 10% w/v PEG 4000, 20% v/v glycerol 0.02 M of each amino acid 0.1 M bicine/Trizma base pH 8.5
H12 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD 0.02 M of each amino acid 0.1 M bicine/Trizma base pH 8.5is to mix equal-volume aliquots of the protein and condition at
297 K, with a 200 nl ﬁnal volume of drops, and to store the
plates at 292 K. Final assessments were made after one week
by manual inspection using a high-powered Leica MX-12
stereomicroscope. A drop was considered a crystallization hit
when it contained protein crystals larger than 20 mm, so that
they could be mounted in a cryoloop for X-ray diffraction.
2.8. Optimization of conditions
Finally, all three components, the ligand mixes, the preci-
pitant mixes and the buffers, are combined using a ﬁxed ratio,
0:5stock precipitants þ 0:1stock additives
þ 0:1buffer system þ 0:3water:
This simple recipe facilitates easy follow-up optimization
experiments. As an initial approach, one can simply change
the above ratios of the stock solutions. The composition of the
buffer systems may be altered during optimization experi-
ments to change the pH. Obviously, all of these optimization
experiments are very amenable to automation (Hennessy et
al., 2009).
3. Results and discussion
Both well known test proteins and novel samples were tried
with MORPHEUS. Table 6 shows all the details and results of
the crystallization trials performed for 16 samples. Fig. 2 shows
the different crystal morphologies observed. All the crystals
shown represent initial hits, except for Scc3 (domain of sister
chromatid cohesion protein 3) and PI3K-I (pi3-kinase p110 in
complex with isoform-speciﬁc inhibitors) which involved
optimization.
Importantly, three samples have crystallized exclusively in
MORPHEUS and produced no hits from any other screen
tried (over 1500 conditions): Scc3, PI3K-I and TriUb-D
(triubiquitin in complex with a ubiquitin-binding domain).
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Table 2
The 47 PDB-derived ligands selected to formulate MORPHEUS.
MPD is (RS)-2-methyl-2,4-pentanediol.
Ligand Residue ID No. of structures
(RS)-Tartaric acid TAR, TLA 113
1,2-(RS)-Propanediol PGR, PGO 41
1,3-Propanediol PDO 7
1,4-Butanediol BU1 11
1,6-Hexanediol HEZ 19
1-Butanol 1BO 7
2-Propanol IPA, IOH 174
Acetate anion ACT, ACY, ACE 1890
Ammonium cation NH4, NH3, NH2 582
Bicine BCN 11
Bromide anion BR 120
Calcium cation CA 3959
Chloride anion CL 2842
Citrate anion FLC, CIT 384
d-Galactose GLA, GAL 86
d-Glucose GLC, BGC 206
Diethylene glycol PEG 209
dl-Alanine ALA, DAL 35
dl-Lysine LYS, DLY 36
dl-Serine SER, DSN 38
d-Mannose MAN, BMA 178
d-Xylose XYP, XYL 33
Ethylene glycol EDO 1081
Fluoride anion F 16
Formic acid FMT 267
Glycerol GOL 2884
Glycine GLY 50
HEPES EPE 201
Imidazole IMD 154
Iodide anion IOD 178
l-Fucose FUC, FUL 62
l-Glutamic acid GLU 28
Magnesium cation MG 3991
MES MES 315
MOPS MPO 21
MPD MRD, MPD 504
N-Acetyl-d-glucosamine NAG 1150
Nitrate anion NO3 156
Oxamic acid OXM 17
Pentaethylene glycol 1PE 91
Phosphate anion PO4, PI, 2HP 1687
Potassium cation K 720
Sodium cation NA 1926
Sulfate anion SO4 5793
Tetraethylene glycol PG4 194
Triethylene glycol PGE 107
Tris TRS 334
Total No. of entries 32908
Table 3
Recipes for preparing the eight MORPHEUS additive mixes.
Stock Composition
Divalent cations 0.3 M magnesium chloride, 0.3 M calcium chloride
Halides 0.3 M sodium ﬂuoride, 0.3 M sodium bromide,
0.3 M sodium iodide
NPS 0.3 M sodium nitrate, 0.3 M disodium hydrogen
phosphate, 0.3 M ammonium sulfate
Alcohols 0.2 M 1,6-hexanediol, 0.2 M 1-butanol, 0.2 M (RS)-1,2-
propanediol, 0.2 M 2-propanol, 0.2 M 1,4-butanediol,
0.2 M 1,3-propanediol
Ethylene glycols 0.3 M diethyleneglycol, 0.3 M triethyleneglycol,
0.3 M tetraethyleneglycol, 0.3 M pentaethyleneglycol
Monosaccharides 0.2 M d-glucose, 0.2 M d-mannose, 0.2 M d-galactose,
0.2 M l-fucose, 0.2 M d-xylose, 0.2 MN -acetyl-
d-glucosamine
Carboxylic acids 0.2 M sodium formate, 0.2 M ammonium acetate,
0.2 M trisodium citrate, 0.2 M sodium potassium
l-tartrate, 0.2 M sodium oxamate
Amino acids 0.2 M sodium l-glutamate, 0.2 M dl-alanine,
0.2 M glycine, 0.2 M dl-lysine HCl, 0.2 M dl-serine
Table 4
Recipes for preparing the four MORPHEUS precipitant mixes.
Composition Frequency Reference
20% w/v PEG 20 000,
40% v/v PEG MME 550
35 Cordell et al. (2003);
Leonard et al. (2004);
Selmer et al. (2006)
20% w/v PEG 8000,
40% v/v ethylene glycol
3T e o et al. (2006)
20% w/v PEG 4000,
40% v/v glycerol
12 Low & Lo ¨we (2006)
25% w/v PEG 3350,
25% w/v PEG 1000,
25% v/v MPD
0 Not publishedThe possible speciﬁcity of ligand mixes can be spotted easily
because of the systematic screen layout: when there are
several hits in the same row of MORPHEUS, it means there is
speciﬁcity to ligands used in the conditions of that row (see
samples PI3K-I, ParR, PAK4G and THM). In the same way,
speciﬁcity to precipitant(s) and pH can easily be noticed (see
Fig. 1). For example, most of the hits with the test sample BAR
were in conditions that integrate the mix of precipitants
developed for MORPHEUS (mix found in columns 4, 8 and
12: 12.5% PEG 1000, 12.5% PEG 3350 and 12.5% MPD).
4. Conclusions
The advantages of designing an initial screen de novo have
been demonstrated. MORPHEUS delivers a screen that is
easy to make and the conditions are easy to optimize. It
contains components that have been selected from crystallized
complexes of previously published structures. It also contains
a limited number of precipitant mixes that have been selected
using local data from the MRC-LMB. MORPHEUS has been
successful in crystallizing both known proteins and important
new samples.
Ideally, more small molecules with interesting character-
istics that are not used in commercially available screens
should be investigated, like some polyols (Cohen et al., 1993).
An extensive set of amine derivatives, including well known
polyamine additives (Ding et al., 1999) and aminated amino
acids (Matsuoka et al., 2007), could form an excellent additive
screen with frozen solutions for storage. Also, protein
chaperones could be added for some challenging crystal-
lizations (Ostermeier et al., 1995; Tereshko et al., 2008). In the
same spirit, it would be interesting to investigate what could
be done with molecules designed to mimic protein–protein
interactions (Allen et al., 1998).
I would like to thank Andrew Turnbull (Cancer Research
Technology Ltd.) and Evangelos Papagrigoriou (Insight
Research Group) for giving early advice. The development of
the screen was sponsored by the MRC-LMB under the
supervision of Jan Lo ¨we and Olga Perisic. The frequency of
the precipitant mixes was revealed by the LMB screen data-
base (http://www2.mrc-lmb.cam.ac.uk/groups/JYL/WWWrobots/
robot.html) developed in collaboration with Paul Hart (MRC-
LMB). Data on triubiquitin, pi3-kinase and plk1 complexes
were given by Yogesh Kulathu, Alex Berndt and Ana Julia
Narvaez, respectively. I would also like to thank everyone at
the MRC-LMB for their assistance in trying MORPHEUS and
providing test samples for two years before its commerciali-
zation. Conﬂicting commercial interest: I hereby state that I
have a conﬂicting commercial interest, in that the MOR-
PHEUS crystallization screen has been commercialized by
Molecular Dimensions Ltd (http://www.moleculardimensions.
com) under an exclusive licence to MRC Technology.
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Table 5
Recipes for preparing the three MORPHEUS buffer systems at different
pH.
pH 1 M MES (ml) 1 M imidazole (ml)
6.1 36.0 14.0
6.3 33.5 16.5
6.5 30.6 19.4
6.7 27.5 22.5
6.9 25.0 25.0
pH 1 M MOPS (ml) 1 M HEPES-Na (ml)
7.1 34.5 15.5
7.3 30.0 20.0
7.5 25.9 24.1
7.7 22.1 37.9
7.9 17.7 32.3
pH 1 M bicine (ml) 1 M Trizma base (ml)
8.1 35.6 14.4
8.3 31.7 18.3
8.5 26.7 23.3
8.7 21.2 28.8
8.9 15.0 35.0
Figure 2
Light micrographs showing 18 crystals obtained with MORPHEUS
(letters refer to Table 6, last column). Magniﬁcations differ and crystal
sizes vary between 20 and 600 mm.References
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